Compare SHC & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHC | GH |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 22.9B |
| IPO Year | 2020 | 2018 |
| Metric | SHC | GH |
|---|---|---|
| Price | $18.73 | $178.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 19 |
| Target Price | $20.33 | ★ $119.79 |
| AVG Volume (30 Days) | ★ 1.8M | 1.7M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 68.75 | 6.74 |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $1,163,617,000.00 | $982,021,000.00 |
| Revenue This Year | $7.51 | $33.30 |
| Revenue Next Year | $6.00 | $28.27 |
| P/E Ratio | $67.68 | ★ N/A |
| Revenue Growth | 5.74 | ★ 32.88 |
| 52 Week Low | $13.09 | $55.38 |
| 52 Week High | $19.85 | $183.51 |
| Indicator | SHC | GH |
|---|---|---|
| Relative Strength Index (RSI) | 50.94 | 62.09 |
| Support Level | $18.20 | $153.88 |
| Resistance Level | $19.79 | N/A |
| Average True Range (ATR) | 0.43 | 8.48 |
| MACD | -0.03 | 1.69 |
| Stochastic Oscillator | 48.47 | 83.84 |
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.